News Hub | News Direct

A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats

NanoViricides, Inc.

By Ernest Dela Aglanu, Benzinga With the COVID pandemic still ongoing, having claimed more than 6.8 million lives from about 758 million cases and crippling the global economy, there are several reasons why drug research and development related to the COVID virus remains highly relevant and necessary. Ongoing drug development by companies such as NanoViricides Inc. (NYSEAMERICAN: NNVC) is vital because new variants of the virus keep emerging and viral infections, hospitalizations and deaths continue at a much greater rate than even pandemic influenza years despite the roll-out of vaccines from players like Novavax Inc. (NASDAQ: NVAX), Moderna Inc. (NASDAQ: MRNA), Oxford– AstraZeneca plc (LON: AZN), and Pfizer Inc. (NYSE: PFE)–BioNTech As new virus variants continue to develop, researchers must stay ahead of the curve to identify and combat them. Given the fast-evolving nature of the virus, early detection of these new variants is thought to be crucial in controlling their spread and preventing further outbreaks. However, with significantly reduced testing worldwide, it is now widely understood that a new damaging variant may not be readily identified before it spreads. Even after 3 years of pandemic, do we have effective drugs that could stop the next variant? Unfortunately, we don’t have even one safe and effective drug that does not come with a lot of limitations. This is why the need to treat current infections and also to better prepare for future pandemics has spurred a new wave of investment and interest in COVID research and development. NanoViricides has recently reported that it is very close to testing its drug candidate NV-CoV-2 to treat SARS-CoV-2 infection in human clinical trials. Thus the Company is nearing an inflection point in its lifecycle, with the first clinical trials of its unique and novel nanomedicines platform. Human clinical trials are now becoming imminent — NanoViricides will no longer be a R&D/Drug Discovery company, but will soon become a clinical-stage pharma company. Traders and investors are taking note of what could be a unique opportunity. NanoViricides, a growing innovator in nanomedicine and antiviral therapies, has been maturing its nanomedicine technology in developing drugs against many viruses for over 15 years, and their most recent developments could potentially prove to be market-disrupting with implications for treating dozens of viruses worldwide. All these years of research and development are coming together for NanoViricides, now, positioning it to potentially become a major player in the antivirals space. NanoViricides has reported: A platform technology that enables it to develop drugs rapidly against many viruses as shown with many candidates in pre-clinical studies against a number of viruses. Technology to make drugs that variants of the virus cannot escape because no matter how much the virus changes, it uses the same receptor, and this company’s technology for first-in-class drugs is based on making copies of that unique receptor. A novel mechanism of action, enabling first-in-class drugs against viruses. Technology to make broad-spectrum antiviral drugs. For example, the company has shown in preclinical studies that its COVID drug works against all the tested coronaviruses. The ability to manufacture first-in-class drugs at scale to make finished drug products for clinical trials of their lead candidate against COVID in its own cGMP compliant manufacturing facility. The COVID drug, NV-CoV-2, has been formulated and tested in the form of Oral Gummies, and also as Oral Syrup - to help COVID-positive patients, including children and older patients who need more accessible treatments. Read the latest report on NanoViricides here. Dosing And Effectiveness NV-CoV-2 Reportedly Superior An additional problem for current COVID cases is that available COVID drugs like remdesivir by Gilead (NASDAQ: GILD), molnupiravir by Merck (NYSE: MRK), and to a lesser extent, Paxlovid by Pfizer (NYSE: PFE) face the challenge of limited dosing for safety reasons — which is a part of why they have limited effectiveness and limitations on use — increasing dosage would not give increased benefit thus limiting the drugs’ capability. Unlike these drugs, the very high safety numbers that NV-CoV-2 has demonstrated in rat studies indicate that patients might be able to take more of the Company’s COVID drug to achieve greater effectiveness when their sickness is more severe. This is expected to be validated in imminent human clinical trials. Once NanoViricides proves that its COVID drug is safe in clinical trials, the company’s entire platform of nanotechnology would essentially be validated as being capable of developing safe drugs. Additionally, assuming NanoViricides demonstrates strong effectiveness of the COVID drug in clinical trials, similar to the strong effectiveness they have reported in their pre-clinical studies, that would validate the Company’s pre-clinical approach in studying effectiveness for developing clinical candidates, and will likely have strong positive implications for the other drug candidates in their pipeline too. As NanoViricides’ reported effective and safe solutions for battling against the COVID pandemic move into the clinic, heralding its official entry as a pharmaceutical drug maker, the story doesn’t stop there. Once the platform is proven, the Company could be well positioned to develop solutions to battle other current and future pandemics as well. The company has drugs nearing clinical stage for treating Shingles and Herpes Viruses (HSV-1 and HSV-2). And it says it will be forging ahead to further develop candidates to battle HIV, Ebola/Marburg, Monkeypox, and other viruses. With the global antiviral therapy market valued at $48.1 billion in 2018 and estimated to garner $79.8 billion by 2026, rising at a compound annual growth rate (CAGR) of 6.7% from 2019 to 2026, NanoViricides could be strategically placed to participate in such significant market size and growth while potentially revolutionize the industry with the Company’s unique biomimetic technology. Head to https://profiles.smallcapsdaily.com/nnvc/ to read more about NanoViricides’ technology. This article originally appeared on Benzinga here. About NanoViricides NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate Remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with Remdesivir encapsulated in it. The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses if the initial research is successful. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details NanoViricides, Inc. +1 203-937-6137 info@nanoviricides.com Company Website http://www.nanoviricides.com

March 20, 2023 09:45 AM Eastern Daylight Time

Hong Kong Baptist University-led research unveils cell entry mechanism of SARS-CoV-2 and therapeutic target for COVID-19

Hong Kong Baptist University

HONG KONG SAR - Media OutReach - 20 March 2023 - A study led by scientists from Hong Kong Baptist University (HKBU) has identified a protease called MT1-MMP that is a major host factor behind the infectivity of the SARS-CoV-2 virus in the human body, which leads to the infection of COVID-19 and multi-organ failure. By applying a humanised antibody called 3A2 that can inhibit the activity of MT1-MMP, the viral load of infected mice was reduced by almost 90%. The research team also demonstrated that the protease is a potential therapeutic target for COVID-19. Dr Xavier Wong Hoi-leong, Assistant Professor, and Dr Guo Xuanming, researcher of the Teaching and Research Division of the School of Chinese Medicine, introduce the research findings on the cell entry mechanism of SARS-CoV-2 and therapeutic target for COVID-19. The research findings have been published in the internationally renowned scientific journal Nature Communications. ACE2 as a receptor for SARS-CoV-2 cell entry Vaccination can protect people against COVID-19 and its potential complications, but it is not always effective in individuals with weak immune systems, or against some COVID-19 variants of concern. Thus, the development of a more effective treatment for COVID-19 remains a huge challenge in the post-vaccine era. Understanding the cell entry mechanism of SARS-CoV-2 is vital to curb the spread of the virus, and it will also aid the search for new COVID-19 treatments. SARS-CoV-2 requires angiotensin-converting enzyme 2 (ACE2), a protein found on the membrane of human cells, as its receptor for cellular entry. Despite the lungs being the major organ affected by SARS-CoV-2 infection, only a small proportion of lung cells express ACE2. Previous studies found that the infection of organs with low levels of ACE2 expression by SARS-CoV-2 is made possible by a soluble form of ACE2. The soluble ACE2 binds with SARS-CoV-2, carries the virus to cells with low levels of ACE2 expression, and facilitates its entry into the cells. MT1-MMP mediates cell entry of SARS-CoV-2 A research team led by Dr Xavier Wong Hoi-leong, Assistant Professor of the Teaching and Research Division of the School of Chinese Medicine at HKBU, in collaboration with Dr Yuan Shuofeng, Assistant Professor of the Department of Microbiology at The University of Hong Kong, further studied how the physiological regulation of soluble ACE2 shedding contributes to the aetiology of COVID-19. The team found that SARS-CoV-2 infection leads to the increased activation of MT1-MMP, a protease crucial for many physiological processes. MT1-MMP mediates the release of soluble ACE2 from ACE2-expressing cells. This soluble ACE2 in turn binds to the spike proteins of SARS-CoV-2 and carries it to the uninfected cells with low levels of ACE2 expression. Notably, the team demonstrated that the introduction of human-soluble ACE2 enables SARS-CoV-2 to infect the lungs of a laboratory mouse strain (C57BL/6 mice) that is naturally insusceptible to SARS-CoV-2 infection due to the incompatibility of its mouse ACE2 and the viral spike proteins. The findings unveil the mechanism by which the virus hijacks host enzymes to enhance its infectivity, triggering multi-organ infections. Antibody 3A2 blocks MT1-MMP activity To study MT1-MMP's functions and how it affects viral infection, the researchers used human cells to create organoids, a 3D tissue structure grown in vitro to resemble and model different organs in the laboratory. They discovered that blocking MT1-MMP activity with the monoclonal antibody 3A2 effectively depleted soluble ACE2 levels and reduced the degree of infection of SARS-CoV-2 in human lung, heart and liver organoids by 60-80%. Consistent results were obtained using the original strain of SARS-CoV-2, as well as variants of concern, such as Delta and Omicron. The results demonstrate that MT1-MMP is a major host factor that mediates the cell entry of SARS-CoV-2, and that it is also a potential therapeutic target for COVID-19 drugs. The researchers further tested the effects of applying 3A2 in a mouse COVID-19 model. A group of 11 mice were treated with either 3A2 or vehicle controls. Older mice were used in the experiment as old age is a major risk factor for severe symptoms and mortality for COVID-19. The results show that 3A2 reduced the viral load of SARS-CoV-2 by almost 90% and dramatically alleviated lung tissue damage resulting from infection. MT1-MMP as a therapeutic target Dr Wong said: "Two major challenges when it comes to developing COVID-19 drugs are how to enhance treatment results for patients with weakened immune systems, and how to maintain the drugs' effectiveness across different viral strains. 3A2 has good potential to become an effective drug for curing COVID-19 because it antagonises the activity of MT1-MMP, instead of boosting the immunity of patients or acting directly on the virus. "Our previous studies have demonstrated that 3A2 also offers protection against obesity and diabetes, two major risk factors for severe symptoms and mortality for COVID-19. Therefore, 3A2 could be particularly suitable for high-risk groups, including older adults and people with metabolic disorders. It could also be effective against emerging coronaviruses in the future, because ACE2 is a doorway for many such viruses with similar cell entry mechanisms. Further research and experiments on 3A2 are required before it can be applied in humans." Contact Details Communication and Public Relations Office Christina Wu christinawu@hkbu.edu.hk

March 20, 2023 09:00 AM Eastern Daylight Time

Image

Kadimastem Earns FDA Approval of its IND Application For its US Multi-Site Phase IIa Clinical Trial of AstroRx® to Treat ALS

Kadimastem Ltd.

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, developing and manufacturing "off-the-shelf" allogeneic cell products using its platform technology to develop treatments for different neurodegenerative diseases and a potential cure for diabetes, has received FDA clearance to commence a phase IIa clinical trial in the US according to the Investigational New Drug (IND) application that was submitted in February 2023. The trial will test its lead neurological cell therapy product AstroRx ® in repeated dosing of three-month intervals for the treatment of patients with ALS. The planned clinical trial follows a first in human phase I/IIa clinical trial previously conducted by the company in Israel, in which AstroRx® was injected into the spinal cord fluid using a standard lumbar puncture procedure. In this phase I/IIa clinical trial Kadimastem demonstrated a good safety profile and clinically meaningful decline in the disease progression during the first 3-months follow-up period. AstroRx® contains functional, healthy astrocytes (nervous system supporting cells) differentiated from human Embryonic Stem Cells (hESC) that aim to support the survival of diseased motor neurons through several mechanisms of action. The treatment’s goal is to nourish and support the malfunctioning motor neurons in the brain and spinal cord of patients suffering from Amyotrophic Lateral Sclerosis (ALS), to significantly slow the progression of the disease and improve the quality of life and life expectancy of the treated patients. Kadimastem CEO Asaf Shiloni said, “The FDA approval for this multi-site clinical trial is a major achievement for us and is a recognition of our professional, clinical and scientific abilities. I’d like to congratulate our dedicated team on this extremely important landmark, which is an enormous milestone that brings great hope for the future of the ALS patients as well as our supporters and investors.” Kadimastem Founder and Chief Scientific Officer Professor Michel Revel said, “The approval of submission of the IND to the FDA is a major achievement and moment of pride for me in the company that I have founded years ago, with an amazing team. It is very exciting, and we eagerly await to start this trial and wish to help ALS patients as soon as possible.” About AstroRx ® & ALS Kadimastem’s flagship product, AstroRx®, is a breakthrough technology that is comprised of a unique and large cell population of astrocytes derived from human pluripotent stem cells. The cells are intended to support the survival of motoneurons (neurons the control the motor-capability) in the central nervous system (CNS, brain and spinal cord). AstroRx® enables the transplantation of healthy astrocytes into the CNS of the ALS patient and an improvement in the protection of the motoneurons. In December 2020, Kadimastem announced the results Kadimastem (TASE:KDST) is a clinical stage biotechnology company, with a unique platform for cell therapy that enables the production of off-the-shelf cell-based products for the treatment of unmet medical needs. of the first of its kind, Phase I/IIa clinical trial, in which healthy and functioning astrocyte cells (AstroRx®) were injected into the spinal fluid of 10 ALS patients. Data showed that AstroRx® has the potential to slow the progression of ALS, as indicated by a clinical score called ALSFRS-R. Kadimastem plans to test repeated doses every three months of AstroRx® to achieve a continuous delay of the disease. This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Sarah Bazak +972 73-797-1601 s.bazak@kadimastem.com GOTLIVE Media Group Lior Gottlieb +972 50-920-0194 lior@gotlive-ir.co.il Company Website https://www.kadimastem.com/

March 20, 2023 07:00 AM Eastern Daylight Time

AMERICAN DIVERSIFIED HOLDINGS CORP (OTC: ADHC) REACHES AGREEMENT FOR COMPREHENSIVE TRANSITION OF ALL BUSINESS OPERATIONS

American Diversified Holdings Corp.

McapMediaWire -- American Diversified Holdings Corporation (OTC: ADHC ) announced today that the Company has filed its quarterly financials ending in 1-31-23. The filing can be found at www.otcmarkets.com under the ticker symbol "ADHC". Additionally plans to divest of all operating business have been initiated in anticipation of a comprehensive transition of all company operations. Agreements have been reached for a new CEO, a New Advisory Board and a new operating business. Additionally, ADHC management has been advised by litigation counsel that a judicial order cancelling 325 mm shares of common stock is expected imminently. Parties a have agreed to refrain from publicizing any details of these agreements until formal execution has taken place. It is anticipated that all developments should be consummated in April, 2023. ADHC has filed suit in The Eight Judicial Circuit Court, Clark County, Nevada case, Number A-21-843-670, seeking the cancellation of 325,000,000 (325 MM) shares of common stock. On January 6, 2023, the court granted the motion for default and will be issuing the formal order soon. The signed court order granting default judgment is the final legal step before all litigation is resolved. Currently, ADHC capitalization structure is as follows: Shares Outstanding: 1.1 billion Shares Restricted: 600 million Shares in the Float: 504 million GLOBAL CBD PET INDUSTRY OVERVIEW: GLOBAL CBD PET MARKET: $198MM 2022; $248MM 2023; $2 BILLION 2030 ANNUAL GROWTH RATE: 31.8 % COMPOUNDED ANNUAL GROWTH RATE E-COMMERCE SEGMENT: 42% OF REVENUES INDICATION: JOINT PAIN, ANXIETY/STRESS, EPILEPSY, GENERAL HEALTH AND WELLNESS see https://www.grandviewresearch.com/industry-analysis/cannabidiol-pet-market About ADHC: American Diversified Holdings Corporation (OTC: ADHC) is a publicly traded holding company trading under the ticker symbol "ADHC". Investor Contact: Ernest Remo Chairman/CEO EMAIL: ernestremo@san.rr.com Tel: 858-259-4534 TWITTER: @ADHCManagement. This Twitter page is the only official Twitter page for ADHC. Information contained herein includes forward-looking statements. These statements relate to future events or future financial performance, involving known and unknown risks and uncertainties that may cause our actual results to be materially different from the performance or achievements expressed. You should not place undue reliance on these statements since they involve known and unknown risks, in some cases, beyond our control. Contact Details Ernest Remo +1 858-259-4534 ernestremo@san.rr.com Company Website https://rollschoiceadhesive.com/

March 20, 2023 06:30 AM Eastern Daylight Time

News Release

BioVaxys acquires TAETSoftware to utilize Trial Adverse Events Tracker platform

BioVaxys Technology Corp

BioVaxys CEO James Passin joins Natalie Stoberman from the Proactive newsroom to discuss the company's acquisition of TAETSoftware, a Vancouver-based clinical studies management company engaged in the development and commercialization of the Trial Adverse Events Tracker (TAET) technology platform. Passin says the acquisition of TAETCO provides BioVaxys with a third low-risk near-term revenue generating product, supporting its core business in cancer and viral vaccine development. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

March 17, 2023 12:08 PM Eastern Daylight Time

Video

News Release

Valeo Pharma sees record quarterly revenue with a triple-digit increase over 1Q 2022

Valeo Pharma Inc.

Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company had a record quarter in the three months to January 31, 2023, with revenue of $13.2 million, up 210% over 1Q 2022. Saviuk tells Proactive this marks the 5th consecutive quarter of growth for the company, with adjusted gross profit increasing by 178% to $4.2 million from a year earlier. Physicians prescribing Enerzair and Atectura reached 1,583 at the end of the first quarter, 39% growth for the quarter and a 799% increase year-over-year. Total annual Enerzair and Atectura prescriptions surpassed 34,000 at the end of 1Q 2023, up 1,917% year-over-year. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

March 17, 2023 11:40 AM Eastern Daylight Time

Video

UAT Group Subsidiary, Ossifix Orthopedics Begins Expansion

Umbra Applied Technologies Group, Inc.

McapMediaWire -- Umbra Applied Technologies Group, Inc. (OTC: UATG ) (UAT Group) announced today that its subsidiary, Ossifix Orthopedics has begun expanding beyond Texas starting with southern and north-eastern part of the United States. Over the past several weeks, the Company has onboarded five new account managers across eleven cities in Texas with expansion into the New England area currently underway. The Company has slated the second fiscal quarter of the year for expansion across four major metropolitan cities in Louisiana and across twenty-one major metropolitan cities in Florida. Ossifix CEO, Mark Estrada, stated: “We are currently in the process of expanding operations and onboarding distribution channels in select target regions. Additionally, in Q2 we will launch two unique foot and ankle product lines.” The Company projects more than one-hundred surgeries to be completed in Q2 alone with a 20% increase month over in growth. Results from initial surgeries have demonstrated early ambulation trend with many patients driving the next day. Results of the surgeries have dramatically increased interest in the Javelin pin which formed the basis for the Company’s decision to start expansion and led to the Company to begin increasing its salesforce. Constructed of select, high-density, allograft, cortical bone, the proprietary design of the Ossifix Orthopedics Javelin pin ensures rigid fixation without pin slip or pirouetting. Manufactured of 100% allograft bone, Ossifix implants are designed for small bone, extremities, and sports medicine markets, but have applications in the craniofacial, spine and oral surgery procedures. Resorbable implant technology is readily accepted and used in today’s market, both domestically and globally. Ossifixs’ unique manufacturing process and designs yield an engineered cortical bone implant that provides secure fixation and virtually eliminates any allergic or autoimmune reactions associated with metal or plastic/polymer implants. All Ossifix Orthopedics Pin, Screw and Plate Systems are single-use surgical kits with all necessary instruments for implantation and are based on decades of clinical experience and use in the operating room. Ossifix products are designed to be used in hospitals, ambulatory surgical centers, and specialty clinics. Distribution is scheduled throughout North America, and globally in Latin America, Europe, Asia Paciﬁc, as well as the Middle East and Africa. This global market is currently experiencing an estimated growth of 14% per year and is expected to reach $4.696 billion in sales this year. Umbra Applied Technologies Group Chief Executive Officer, Alex Umbra, commented, "The growth and interest that Ossifix has experienced is unprecedented. With the launch of their additional product suites coming later this year, Ossifix will be a disrupting force within a niche but significant market segment”. Ossifix Orthopedics will continue to meet with hospital systems, surgical centers and orthopedic surgeons across the U.S. with international sales slated to begin later this year. For more information about Ossifix Technologies go here: https://ossifixtech.com/ About Umbra Applied Technologies Group, Inc. The firm is located in Tampa Florida and focuses on advanced technologies across many disciplines. UAT Group is a holding company with interests in both public and private companies during the early stages of development as well as growth stages of companies with a synergistic business model to UAT Group subsidiaries. For more information, visit: www.uatgroup.com Investor and Media Contact: info@uatgroup.com NEITHER THE SECURITIES EXCHANGE COMMISSION NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE. Forward-Looking Information This news release may include "forward-looking statements" including forecasts, estimates, expectations, and objectives for future operations including but not limited to its ability to conclude a business combination with a third party, sale of assets, return of capital or initial public offering and a secondary listing on the OTC as a result of aforementioned and its ability to fund the exploration of its assets through the raising of equity or debt capital or through funding by a joint venture partner that are subject to a number of assumptions, risks, and uncertainties, many of which are beyond the control of Umbra Applied Technologies Group including but not limited to capital markets and securities risks and continued development success on technology. There can be and are no actual or implied guarantees that any of the above activities will be completed or completed on terms acceptable to the Company and its shareholders or approved by any regulatory authority having jurisdiction. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Umbra Applied Technologies Group does not assume the obligation to update any forward-looking statement, except as required by applicable law. Contact Details Umbra Applied Technologies Group, Inc. info@uatgroup.com

March 17, 2023 08:00 AM Eastern Daylight Time

American Center for Cures Co-Founder Appointed by President Biden to National Cancer Advisory Board

The American Center for Cures

The American Center for Cures (ACC) today announced its long-time partner and co-founder Dr. Richard Boxer has been selected by President Joseph Biden to the National Cancer Advisory Board. In this role, Dr. Boxer will use his years of medical expertise to help guide the Director of the National Cancer Institute in the development of the organization’s national cancer research. Along with venerated entrepreneur Lou Weisbach, Dr. Boxer co-founded the ACC as a bipartisan initiative that aims to unite medicine, science, pharmaceuticals, business, and government to seek out new treatments and cures for Alzheimer’s, diabetes, Parkinson’s, mental diseases, many forms of cancer, and several others. “Richard Boxer and I have worked together on this important endeavor for more than a decade. It’s an honor to see him elevated to the National Cancer Advisory Board,” said Lou Weisbach, CEO and Co-Founder of ACC. “I’ve been working in a bipartisan way with leaders of both parties and the quote from Tom Price, former Secretary of Health, tells you all you need to know about our mission: ‘When this plan is approved it will rival the greatest achievements in US history and offer the sense of urgency that all American families yearn for and deserve when battling disease.’” Dr. Boxer, a UCLA Clinical Professor and Co-Founder of the American Center for Cures added: “I’ve dedicated my professional career to compassionate and uncompromising care for cancer patients and educating the public and the medical community and preventing and curing disease is a critical single issue that all Americans can agree on. As a practicing urologist treating cancer patients and cancer survivor myself, the mission of the ACC and my role in its success is very personal.” Dr. Boxer, a Clinical Professor at the David Geffen School of Medicine at UCLA, himself a three-time cancer survivor, has been practicing medicine for 44 years, caring for more than 7,000 patients with cancer and tens of thousands of patients with other illnesses. He represented the U.S. at the World Health Organization as a private citizen, a finalist for Surgeon General of the United States in both a Democratic and Republican Administration, and he was recently on the Board of Directors of the American Society of Clinical Oncology Conquer Cancer Foundation. Dr. Boxer has published nearly 100 journal articles and book chapters on medical research and has also written extensively on health policy in national press outlets. He helped create the initial clinical protocols for telemedicine, becoming the Chief Medical Officer of numerous telemedicine companies. In April 2021, he was awarded the Distinguished Alumni Award by the University of Wisconsin’s Medical School, its highest honor. “This is a critical single issue that all Americans can agree on, whether they be black or white, rich or poor, Democrat or Republican,” declared Weisbach. “With kudos to all medical breakthroughs of the past, we still haven’t gotten the job done in a business-like fashion as a nation when it comes to prevention and cures. That ends today. We are not asking congress or both parties to move forward on this initiative, we are insisting that it be passed unanimously. This issue impacts all 335 million Americans in the same way, including everyone in The White House, as well as members of Congress and their families. If we cannot unite on this issue as Americans, then I submit there are no issues on which we can unite.” About American Center for Cures The American Center for Cures (ACC) initiative is a fully funded mission to prevent, treat or cure diseases that plague every American family. The initiative will be funded by the sale of $750B bonds by the Federal Reserve, providing the capital needed to accelerate the current trajectory of medicine. Annual interest will be paid through the licensing of new compounds and drugs to pharmaceutical companies. The principal will be repaid by savings provided to the United States Government through successes in the areas of prevention and cures. The ACC business model will cost the government and taxpayers nothing, making this the single most impactful investment on behalf of the American people in the nation’s history. For more information, please visit https://theamericancenterforcures.org. Contact Details Jenna Beaucage +1 508-340-6851 jbeaucage@rainierco.com Company Website https://theamericancenterforcures.org

March 15, 2023 02:33 PM Eastern Daylight Time

News Release

NuggMD Launches Leading Marijuana Telemedicine Service in Georgia

NuggMD

NuggMD, the nation's leading medical marijuana telemedicine platform, has launched its service in Georgia. For $139, Georgians can now use NuggMD’s platform to connect with a medical professional who can recommend cannabis for treatment of the state’s qualifying conditions. The launch comes amid a tense political, legal, and regulatory climate in Georgia for cannabis businesses and consumers. In 2019, Gov. Brian Kemp (R) signed into law HB 324, which legalized low-THC medical cannabis oil in the state. However, that law has yet to be successfully implemented, with only two production facilities having been awarded licenses in the subsequent four years. While newly proposed legislation, HB 196, seeks to allow more cannabis licenses, its political fate is uncertain. Additionally, Georgia remains one of the dwindling states that still impose jail time for simple possession of unlicensed cannabis. Despite lacking a single legal cannabis dispensary and the fact that no provision in Georgia law suggests how a patient might lawfully obtain cannabis, an estimated 25,000 medical cannabis patients currently reside in Georgia, and the overall demand for legal cannabis is far greater. Alex Milligan, co-founder and CMO of NuggMD, said, "Georgia still has unfair criminal statutes for the simple possession of cannabis, which runs counter to the 2019 law that legalized some forms of the substance. As one of the only services Georgians can rely on to lawfully access cannabis, the irony of this contradiction is not lost on us. One way or another—and in accordance with state law—the availability of legal cannabis will soon be a reality in Georgia. We’ve expanded our operations there so that Georgians can prepare for this eventuality by receiving cannabis recommendations from credible, licensed medical professionals.” NuggMD's platform is available from 8 am until 10 pm local time, seven days a week. No appointment is needed, and patients who are deemed not to qualify for Georgia's medical cannabis program won't be charged for their evaluation. Since its founding in 2015, NuggMD has helped more than 1,000,000 patients access medical marijuana in nearly half of the nation's states. About NuggMD NuggMD is the nation's leading medical marijuana technology platform, serving patients in California, Connecticut, Georgia, Illinois, Iowa, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, and West Virginia. They've connected over 1,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit NuggMD.com. Contact Details Andrew Graham andrew.g@getnugg.com Company Website http://www.nuggmd.com

March 15, 2023 02:30 PM Eastern Daylight Time

Healthcare

A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats

Hong Kong Baptist University-led research unveils cell entry mechanism of SARS-CoV-2 and therapeutic target for COVID-19

Kadimastem Earns FDA Approval of its IND Application For its US Multi-Site Phase IIa Clinical Trial of AstroRx® to Treat ALS

AMERICAN DIVERSIFIED HOLDINGS CORP (OTC: ADHC) REACHES AGREEMENT FOR COMPREHENSIVE TRANSITION OF ALL BUSINESS OPERATIONS

BioVaxys acquires TAETSoftware to utilize Trial Adverse Events Tracker platform

Valeo Pharma sees record quarterly revenue with a triple-digit increase over 1Q 2022

UAT Group Subsidiary, Ossifix Orthopedics Begins Expansion

American Center for Cures Co-Founder Appointed by President Biden to National Cancer Advisory Board

NuggMD Launches Leading Marijuana Telemedicine Service in Georgia